| Document |
Document Title |
|
JP3181589B2 |
PCT No. PCT/EP91/02493 Sec. 371 Date Oct. 27, 1993 Sec. 102(e) Date Oct. 27, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11277 PCT Pub. Date Jul. 9, 1992Compounds of the general formula I (I) are described, in which x represents an ox...
|
|
JP2001508079A |
PCT No. PCT/EP98/00377 Sec. 371 Date Jul. 14, 1999 Sec. 102(e) Date Jul. 14, 1999 PCT Filed Jan. 13, 1998 PCT Pub. No. WO98/31702 PCT Pub. Date Jul. 23, 1998The present invention relates to certain 16-hydroxy-11-(substituted phenyl)-estr...
|
|
JP2001506663A |
(57) [Summary] General formula (I): {In formula, R1Is hydrogen, alkyl, acyl, fluorine, and X1R5(Here, X1Represents oxygen and sulfur, and R5Can be hydrogen, alkyl, or aryl. ), R2Represents hydrogen and alkyl; the stereochemistry of C-13,...
|
|
JP2001503732A |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
JP2001502341A |
A process for treating human skin by inhibiting serine protease formation involving contacting the skin with a composition containing a sterol sulfate.
|
|
JP2001502350A |
The invention relates to a new polymorphic crystalline form of S-fluoromethyl 6alpha,9alpha-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-1
7alpha-propionyloxyandrosta-1,4-diene-17beta-carbothiate (fluticasone propionate). The new polymor...
|
|
JP2001502328A |
This invention provides 17 alpha , DELTA 8,9-dehydroestradiol or a pharmaceutically acceptable salt of its 3-sulfate ester, and 17 beta , DELTA 8,9-dehydroestradiol or a pharmaceutically acceptable salt of its 3-sulfate ester.
|
|
JP2000309536A |
To obtain the subject composition useful for treating prostatic adenocarcinoma by including a specific steroid 5-α-reductase inhibiting compound and a carrier. This pharmaceutical composition is obtained by including (A) a steroid 5-α-...
|
|
JP2000513380A |
There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable o...
|
|
JP3096480B2 |
Bile acid derivatives of formula I wherein : R is hydrogen or hydroxy; X is a carboxy or a SO3H group, have valuable pharmacologic properties.
|
|
JP2000273099A |
To produce the subject derivative having a halogen atom at a specific position, capable of allowing various side chains to be introduced by utilizing the reactivity of the halogen atom, capable of allowing a protection step and a deprote...
|
|
JP2000264899A |
To obtain a steroid external preparation having excellent dispersibility in a base and emulsion stability, useful for treating acute eczema, atopic dermatitis, infantile eczema, etc., by making the external preparation include a specific...
|
|
JP2000509016A |
Disclosed are (i) compounds of a steroid, a beta-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous produc...
|
|
JP3065109B2 |
Products of formula (I): in which: R = H, alkyl, alkenyl, alkynyl, haloalkyl or alkylthio, (-> 6c) or arylthio, aryl, acyl (-> 12c) or CN (CH2)m-Rc in which Rc denotes OH, SH or Salk (1 to 6c), cycloalk (3 to 6c), m = 1, 2 or 3, X = O N-...
|
|
JP2000508333A |
The subject of the invention is the products of formula (I):in which either R1 represents halogen, hydroxyl, (C1-C8) alkyloxy or (C1-C12) acyloxy, and R2 represents halogen or hydrogen, or R1 and R2 form together a double bond, Z is chos...
|
|
JP3056770B2 |
Products of general formula (I): in which R1 denotes an aliphatic hydrocarbon radical, R2 and R3, which are identical or different, denote a hydrogen atom or an alkyl radical, G denotes a hydrocarbon group containing from one to eighteen...
|
|
JP3040175B2 |
The invention relates to novel sulphamate derivatives of 1,3,5(10)-estratriene derivatives of general formula (I) in which the 3-sulphamate group is acylated, sulphonated or amido-sulphonated. Also disclosed are methods of producing thes...
|
|
JP3037508B2 |
PURPOSE: To obtain a new substd. 16-methyl-steroid deriv. of pregna-1,4- diene-3,20-dione useful as an intermediate for the synthesis of 16-methylene steroid. CONSTITUTION: The substd. 16-methyl-steroid deriv. is a compd. of formula I [w...
|
|
JP3036141B2 |
PURPOSE: To provide the title novel compound having high nonlinear optical performance for wavelength transformation, etc., thus useful for nonlinear optical materials and nonlinear optical elements. CONSTITUTION: The objective compound ...
|
|
JP3037427B2 |
Starting compounds for preparing calcitriol (1$g(a), 25-dihydroxycholecalciferol) and its derivatives showing, as compared with calcitriol, some modifications, particularly in the C-17 lateral chain, a method for preparing these starting...
|
|
JP2999257B2 |
PCT No. PCT/EP91/01017 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18917 PCT Pub. Date Dec. 12, 1991.The invention includes compounds of the following formula where A and B either A...
|
|
JP2999258B2 |
PCT No. PCT/EP91/01018 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18918 PCT Pub. Date Dec. 12, 1991.A process for the production of 10 beta -H-11 beta -(substituted phenyl) steroid...
|
|
JPH11513684A |
Compounds of the formula I I are inhibitors of 5 alpha -reductase, and are useful for the treatment of hyperandrogenic disorders such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness, prostatic carcinoma, prostatitis ...
|
|
JPH11512402A |
The invention is directed to compounds, compositions and method of preparation of compounds of formulae I and II:wherein X, Q1, Q2, R1 and R2 are as defined by the specification. The compounds are disclosed as useful cholesterol-lowering...
|
|
JP2961187B2 |
The invention relates to the products of the formula (I): …… in which:… R = alkyl, alkenyl, alkynyl or CN,… R1 = C1-6-alkyl which is unsubstituted or substituted by one or more radicals chosen from among C1-4-alkoxy or alkylthio,...
|
|
JP2947945B2 |
PCT No. PCT/GB96/03153 Sec. 371 Date Jun. 24, 1998 Sec. 102(e) Date Jun. 24, 1998 PCT Filed Dec. 19, 1996 PCT Pub. No. WO97/24367 PCT Pub. Date Jul. 10, 1997Compounds of the pregnane series are described having general formula (I) or the...
|
|
JP2947944B2 |
Compounds of the androstane series are described having general formulaand solvates thereof, in which R1 represents O, S or NH; R2 individually represents OC(=O)C1-6 alkyl; R3 individually represents hydrogen, methyl (which may be in eit...
|
|
JPH11505268A |
The invention relates to novel sulphamate derivatives of 1,3,5(10)-estratriene derivatives of general formula (I) in which the 3-sulphamate group is acylated, sulphonated or amido-sulphonated. Also disclosed are methods of producing thes...
|
|
JP2838543B2 |
|
|
JP2828780B2 |
Novel substituted steroid compounds are disclosed which are more effective than known radical-trapping agents in methods of prophylaxis and therapy of radical-mediated cell damage and of treatment of diseases due to radical-mediated cell...
|
|
JPH10509692A |
The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors. The steroids are useful as ligands to neuroepithelial receptors in the human vomeronasal gland to stimulate ...
|
|
JPH10509423A |
The invention relates to estrene steroids, which bind to neuroepithelial cells in the human vomeronasal organ. The steroids are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically a...
|
|
JP2794297B2 |
Products of formula (I): in which: R1 = optionally substituted carbocyclic or heterocyclic aryl or aralkyl radical, R2 = in position alpha or beta = hydrocarbon radical of 1 to 18 carbon atoms, X = -(CH2)n- with n = 1, 2 or 4 or X = -CH=...
|
|
JP2785017B2 |
Products of the formula in which R1 = C1-18 organic radical R2 = CH3 or C2H5 A and B Re = H, C1-6 Alk or acyl R3 or R4 denote: one optionally protected or acylated OH or alkoxy and the other optionally substituted aryl, R5: optionally su...
|
|
JPH10507176A |
The disclosed invention is a process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids from 3-halo-17-beta-substituted-androsta-3,5-dienes. The process may be performed in either of two ways: (1) the 3-halo compound ...
|
|
JP2768864B2 |
PURPOSE: To obtain a new amine compd. as an intermediate of an amine steroid useful in the treatment of medulla spinalis injury, head injury, subarachnoid hemorrhage, asthma, muscular dystrophy, skin graft rejection, septic shock, etc. C...
|
|
JP2742331B2 |
Compounds of the general formula (1> wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R<14> represents a hydrogen atom a halogen atom or an alky...
|
|
JPH10101567A |
To obtain the subject composition enabling estrogen therapy and the supplement of estrogen to mammals, in which the increase of prolactin level accompanying estrogen administration is unwanted, by compounding dehydroestorone, etc., havin...
|
|
JPH1081625A |
To obtain a medicinal composition useful for treatment of prostatic adenocarcinoma by containing a depressant compound for steroid 5-α-reductase and a medicinally permissible carrier. As a compound of steroid 5-α-reductase inhibitor, 1...
|
|
JP2729320B2 |
19-Substituted progesterone derivatives and related compounds which are active as 19-hydroxylase inhibitors and useful as antihypertensive agents are described herein. The compounds are prepared using appropriate synthetic pathways which...
|
|
JPH10502648A |
The invention relates to novel chelate formers containing sulphonamide groups and their metallic chelates of general formula (I) in which n, m, p, V<1>, V<2>, V<3>, V<4>, X<1>, X<2>, X<3>, R<1>, R<2>, R<3> and R<4> have different meaning...
|
|
JP2718834B2 |
|
|
JP2717792B2 |
Novel 19-nor-steroids of the formula (I) wherein the A ring is either Re is selected from the group consisting of hydrogen, acyl and optionally substituted alkyl of 1 to 6 carbon atoms, R is methyl or ethyl, R1 is selected from the group...
|
|
JP2710789B2 |
|
|
JP2702280B2 |
Invented is a Method of Treating Prostatic Adenocarcinoma by employing asteroid 5- alpha -reductase inhibiting compound or a combination of steroid 5- alpha -reductase inhibiting compounds.
|
|
JP2699766B2 |
PURPOSE: To provide a new fluoride analog of vitamin D3 having excellent pharmacologic action, especially antitumor activity caused by the action to induce the cell differentiation from tumor cell to normal cell. CONSTITUTION: The compou...
|
|
JP2695044B2 |
PCT No. PCT/AU92/00132 Sec. 371 Date Sep. 21, 1993 Sec. 102(e) Date Sep. 21, 1993 PCT Filed Mar. 27, 1992 PCT Pub. No. WO92/17788 PCT Pub. Date Oct. 15, 1992.The present invention relates to electrode membrane combinations for use in bio...
|
|
JPH09512270A |
The present invention relates to methods and compositions for the transformation of cells. In particular, compositions and methods are disclosed which include combinations of the nucleic acid of interest and polyhydroxylated or polyglyco...
|
|
JP2687209B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JP2684180B2 |
PCT No. PCT/FR87/00096 Sec. 371 Date Nov. 25, 1987 Sec. 102(e) Date Nov. 25, 1987 PCT Filed Mar. 26, 1987 PCT Pub. No. WO87/05908 PCT Pub. Date Oct. 8, 1987. (I) (II) (III) (IV) (V) (VI) Products having the formula (I) wherein R1 is an a...
|
